FR2687070A1 - Concentrated solution for haemodialysis with anticoagulant power for extra corporeal circulation. - Google Patents
Concentrated solution for haemodialysis with anticoagulant power for extra corporeal circulation. Download PDFInfo
- Publication number
- FR2687070A1 FR2687070A1 FR9201331A FR9201331A FR2687070A1 FR 2687070 A1 FR2687070 A1 FR 2687070A1 FR 9201331 A FR9201331 A FR 9201331A FR 9201331 A FR9201331 A FR 9201331A FR 2687070 A1 FR2687070 A1 FR 2687070A1
- Authority
- FR
- France
- Prior art keywords
- agent
- pharmaceutical composition
- patient
- composition according
- coagulant agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 37
- 238000001631 haemodialysis Methods 0.000 title claims abstract description 19
- 229940127219 anticoagulant drug Drugs 0.000 title description 2
- 229940127090 anticoagulant agent Drugs 0.000 claims abstract description 34
- 239000000243 solution Substances 0.000 claims abstract description 22
- 229920000669 heparin Polymers 0.000 claims abstract description 17
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960002897 heparin Drugs 0.000 claims abstract description 12
- 238000000502 dialysis Methods 0.000 claims abstract description 10
- 239000002243 precursor Substances 0.000 claims abstract description 8
- 239000012528 membrane Substances 0.000 claims abstract description 7
- 229940127215 low-molecular weight heparin Drugs 0.000 claims abstract description 5
- 239000012141 concentrate Substances 0.000 claims abstract description 4
- 239000000385 dialysis solution Substances 0.000 claims abstract description 4
- 239000003055 low molecular weight heparin Substances 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 230000000322 hemodialysis Effects 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 230000010100 anticoagulation Effects 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000000004 hemodialysis solution Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
La présente invention concerne les solutions concentrées pour hémodialyse destinées à réaliser après dilution un bain de dialyse, ou dialysat, qui sera échangé avec le sang d'un malade insuffisant rénal à travers un filtre selon la technique d'hémodialyse. The present invention relates to concentrated solutions for hemodialysis intended to carry out after dilution a dialysis bath, or dialysate, which will be exchanged with the blood of a patient with renal insufficiency through a filter according to the hemodialysis technique.
Pour réaliser cette technique de traitement qui dure quatre heures en moyenne, il est nécessaire de réaliser une anticoagulation du sang du patient afin d'éviter la coagulation de la circulation extra-corporelle. To carry out this treatment technique which lasts an average of four hours, it is necessary to carry out an anticoagulation of the patient's blood in order to avoid coagulation of the extra-corporeal circulation.
Habituellement cette anticoagulation est réalisée à laide d'héparine classique qui est administrée soit en doses discontinues; sous forme d'une dose dite "de charge" lors de l'amorcage de la circulation extra-corporelle et d'une dose dite "d'entretien" prenant place au milieu de la dialyse. Usually this anticoagulation is carried out using conventional heparin which is administered either in discontinuous doses; in the form of a so-called "loading" dose when priming the extra-corporeal circulation and a so-called "maintenance" dose taking place in the middle of dialysis.
Les doses d'héparine sont habituellement réalisées de façon empiriques en fonction de la constatation visuelle d'absence ou de présence de caillots sanguins dans le circuit de circulation extra-corporelle. mode d'administration entraine parfois une anti-coagulation pour le patient lui même bien supérieure aux normes habituellemnt cherchées étant parfois trois ou quatre fois plus anti@coagulé qu'un témoin alors que deux fois suffisent.Heparin doses are usually performed empirically based on the visual finding of the absence or presence of blood clots in the extracorporeal circulation circuit. mode of administration sometimes leads to an anti-coagulation for the patient himself much higher than the norms usually sought being sometimes three or four times more anti @ coagulated than a control while twice enough.
Une autre facont d'administrer l'héparine consiste. en une administration dite "continue", avec ou sans dose de charge", à.l'aide d'un pousse-seringue. Another way to administer heparin is. in a so-called "continuous" administration, with or without a loading dose ", using a syringe pump.
Ce mode d'administration plus sûr mais plus couteux nécessite un équipement complémentaire, intégré ou non à l'appareil de dialyse et des seringues spéciales, avec tubulures adaptées. This safer but more expensive method of administration requires additional equipment, whether or not integrated into the dialysis machine and special syringes, with suitable tubing.
Plus récemment sont apparues les héparines dites de "bas poids moléculaire", ayant l'avantage d'assurer un effet anticoagulant, par action antt-thrombotique importante, sans action significative.--sur le saignement. More recently, so-called "low molecular weight" heparins have appeared, having the advantage of ensuring an anticoagulant effect, by significant antt-thrombotic action, without significant action - on bleeding.
Les héparines debas poids moléculaire ne modifient pas l'agrégation plaquettaire ni la fixation du fibrinogène sur les plaquettes. Low molecular weight heparins do not affect platelet aggregation or the binding of fibrinogen to platelets.
Le problme.lié;.à l'utilisation de ces produits lors des techniques d'hémodialyse chronique réside dans leur coût Duisqu!ils sont, à effet clinique équivalent, environ 10 fois plus cher que.-l'-héparine classique. The problem related to the use of these products during chronic hemodialysis techniques lies in their cost Since they are, with equivalent clinical effect, approximately 10 times more expensive than conventional heparin.
Le principe de notre invention consiste à réaliser des solutions concentrées pour hémodialyse comportant un agent anticoagulant ou un précurseur d'un agent anti-coagulant dans leur formule, alors que cela n'existe pas actuellement dans les solutions concentrées disponibles auprès de l'industrie pharmaceutique. The principle of our invention consists in producing concentrated solutions for hemodialysis comprising an anticoagulant agent or a precursor of an anti-coagulant agent in their formula, whereas this does not currently exist in the concentrated solutions available from the pharmaceutical industry. .
L'adjonction d'un agent anti-coagulant dans les solutions concentrées aura un double avantage:
10) La distribution de l'agent anti-coagulant au patient sera assurée de façon continue tout au long de la séance -d1hémodialyse sana adjonction de matériel complémentaire et sans consommation d'énergie puisqu1elle aura lieu à travers l'hémodialyseur@(filtre pour hémodialyse) grâce au gradient de concentration qui existera alors entre le dialysat comportant agent anti-coagulant et le sang du patient qui n'en contient pas.The addition of an anti-coagulant agent in concentrated solutions will have a double advantage:
10) The distribution of the anti-coagulant agent to the patient will be ensured continuously throughout the session -d1 hemodialysis without the addition of additional equipment and without energy consumption since it will take place through the hemodialysis machine @ (filter for hemodialysis ) thanks to the concentration gradient which will then exist between the dialysate comprising anti-coagulant agent and the patient's blood which does not contain it.
2 ) La filtration de..-l'héparine classique à travers la membrane de dialyse,: "dans le cas ou celle-ci serait. utilisée comme agent anti-coagulant, selectionne les fragments de bas poids moiéculaire et seuls ceux-ci pénètrent dans l'organisme, .assurant ainsi une anti-coagulation à l'aide dthéparine de bas poids moléculaire de façon très économique. 2) Filtration of ..- classic heparin through the dialysis membrane: "in the event that it is used as an anti-coagulant, selects fragments of low molecular weight and only these penetrate in the body, thus ensuring anti-coagulation using low molecular weight heparin in a very economical manner.
Lwhéparine classique, ou non fractionnée, est en effet un mélange hétérogène ce channes polysaccharidiques de diverses longueurs dont le poids moléculaire -stéchelonne de 3.000 à 40.000 D. The conventional or unfractionated heparin is in fact a heterogeneous mixture of polysaccharide chains of various lengths, the molecular weight of which ranges from 3,000 to 40,000 D.
Les héparines de bas: poids moléculaire sont obtenus par fractionnement à partir de l'héparine standard , elles sont constituées de chaînes polyssaccharidiques plus petites et plus homogènes dont le poids moléculaire varie de 2.500 à 8.000 D,
tes poids moléculiares de ces fragments plus légers leur permet donc de traverser les membranes actuellement utilisées en hémodialyse et d'avoir ainsi un fractionnement spontané de l'héparine standard: si-celle-ci se trouve dans le dialysat.Low heparins: molecular weight are obtained by fractionation from standard heparin, they consist of smaller and more homogeneous polyssaccharide chains whose molecular weight varies from 2,500 to 8,000 D,
the molecular weights of these lighter fragments therefore allow them to cross the membranes currently used in hemodialysis and thus to have a spontaneous fractionation of standard heparin: if it is in the dialysate.
D'autres agents d'anti-coagulation peuvent être utilisés dans le bain de dialyse dès l'instant que leur poids moléculaire leur.permet!de traverser les membranes utilisées lors des séances d'hémodialyse. Other anti-coagulation agents can be used in the dialysis bath as soon as their molecular weight allows them to pass through the membranes used during hemodialysis sessions.
Des précurseurs d'agents anti-coagulants peuvent être adjoints dans les solutions concentrées dès lors que leur réaction avec d'autres composés présents dans le dialysat conduira à la formation d'un agent anti-coagulant. Precursors of anti-coagulant agents can be added to the concentrated solutions as soon as their reaction with other compounds present in the dialysate will lead to the formation of an anti-coagulant agent.
Citons par exemple l'acide citrique qui pourrait être utilisé pour son pouvoir acidifiant dans les, solutions dites "acides" concentrés pour hémodialyse, à la place de l'acide acétique.-
La réaction de l'acide citrique et du bicarbonate de sodium :présents dans les concentrés dits "bicarbonate" entrainera la formation de citrate de sodium, agent anti-coagulant de faible poids moléculaire, qui traversera la membrane d'hémodialyse pour diffuser dans 1 organisme du patient. Let us quote for example citric acid which could be used for its acidifying power in the solutions called "acids" concentrated for hemodialysis, instead of acetic acid.
The reaction of citric acid and sodium bicarbonate: present in so-called "bicarbonate" concentrates will lead to the formation of sodium citrate, an anti-coagulant agent of low molecular weight, which will cross the hemodialysis membrane to diffuse in 1 organism of the patient.
Ainsi plusieurs. types de solutions concentrées pour hémodialyse contenant des agents anti-coagulants pourront être réalisées:
10) Des solutions concentrées destinées à réaliser une hémodialyse à l'aide de l'acétate de sodium comme tampon alcalin dont la composition comportera alors:
. Du chlorure de.sodium (NaCl)
. Du chlorure de potassium (KC1)
..Du chlorure de calcium (Ca C12)
. Du chlorure de magnésium (MgCl2)
. De l'acétate de sodium
, De l'héparinate, de sodium ou un autre agent anticoagulant et éventuellement du glucose chacun de ces corps pouvant être présents dans des proportions variées en fonction des indications des prescripteurs.So many. types of concentrated hemodialysis solutions containing anti-coagulant agents can be produced:
10) Concentrated solutions intended to carry out a hemodialysis using sodium acetate as an alkaline buffer, the composition of which will then comprise:
. Sodium chloride (NaCl)
. Potassium chloride (KC1)
..Calcium chloride (Ca C12)
. Magnesium chloride (MgCl2)
. Sodium acetate
, Heparinate, sodium or another anticoagulant agent and possibly glucose, each of these bodies being able to be present in varied proportions according to the indications of the prescribers.
20) Des solutions concentrées destinées à réaliser une hémodialyse à l'aide du bicarbonate de sodium comme tampon alcalin; utilisant alors deux solutions concentrées distinctes, l'agent anticoagulant pouvant être adjoint à l'une ou l'autre des solutions, ainsi.la solution concentrée dite acide aurait la formule suivante comportant. 20) Concentrated solutions intended to carry out a hemodialysis using sodium bicarbonate as an alkaline buffer; then using two separate concentrated solutions, the anticoagulant agent being able to be added to one or the other of the solutions, thus. the concentrated solution called acid would have the following formula comprising.
Du chlorure.de sodium .(NaCl)
. Du chlorure de potassium (KCl)
. Du chlorurre de calcium (CaCl2)
. Du chlorure de magnésium (MgCl2)
. De ltacide acétique
. De l'héparinate de sodium ou un autre agent anticoagulant et éventuellement du glucose chacun de ces composés pouvant être présents dans des proportions variables selon le prescripteur.Sodium chloride (NaCl)
. Potassium chloride (KCl)
. Calcium chloride (CaCl2)
. Magnesium chloride (MgCl2)
. Acetic acid
. Sodium heparinate or another anticoagulant agent and optionally glucose each of these compounds may be present in variable proportions depending on the prescriber.
Le même type de concentré "acide" peut aussi être réalisé en remplaçant l'acide acétique par de l'acide chlorhydrique. The same type of "acid" concentrate can also be produced by replacing acetic acid with hydrochloric acid.
Si agent anti-coagulant est ajouté dans la solution concentrée dite bicarbonate la formule de cette solution comportera alors:
Du chlorure de sodium < NaCl)
Du bicarbonate de sodium (NaHCO3)
De De l'héparinate de sodium ou un autre agent anticoagulant là encore ces composés pouvant être associés en quantité variable selon les indications des prescripteurs.If an anti-coagulant agent is added to the concentrated solution called bicarbonate the formula of this solution will then include:
Sodium chloride <NaCl)
Sodium bicarbonate (NaHCO3)
Sodium heparinate or another anticoagulant agent, again these compounds can be combined in variable quantities according to the indications of the prescribers.
Enfin, il pourra être adjoint non pas un agent anti -coagulant lui même mais un précursuer d'agent anti-coagulant qui par action avec un autre composé présent dans le dialysat formera l'agent anti-coagulant lui-même ainsi par exemple si l'acide citrique est utilisé à la place de l'acide acétique dans la Solution concentrée dite "acide" il se formera par réaction avec le bicarbonate de sodium présent dans le dialysat du citrate de sodium, agent anti-coagulant habituellement utilisé en transfusion sanguine, qui de par son faible poids moléculaire traversera la membrane du filtre utilisé lors des séances d'hémodialyse. La composition de ces solutions concentrées comportera alors:
. Du chlorure de sodium (NaCl)
Du chlorure de potassium (KC1)
. Du chlorure de calcium (CaC12)
. Du chlorure de magnésium (MgC12)
De l'acide citrique et éventuellement du glucose selon les indications des prescripteurs.Finally, it may be added not an anti-coagulant agent itself but a precursor of an anti-coagulant agent which by action with another compound present in the dialysate will form the anti-coagulant agent itself thus for example if the citric acid is used in place of acetic acid in the so-called "acid" concentrated solution, it will form by reaction with the sodium bicarbonate present in the sodium citrate dialysate, an anti-coagulant agent usually used in blood transfusion, which due to its low molecular weight will cross the membrane of the filter used during hemodialysis sessions. The composition of these concentrated solutions will then include:
. Sodium chloride (NaCl)
Potassium chloride (KC1)
. Calcium chloride (CaC12)
. Magnesium chloride (MgC12)
Citric acid and possibly glucose as prescribed by prescribers.
Enfin 1adjonction d'un agent anti-coagulant' pourra se faire directement dans le liquide d'hémodialyse dans le cadre de la dialyse péritonéale, par adjonction dans les poches utilisées pour réaliser la dialyse péritonéale. Finally, the addition of an anti-coagulant agent can be done directly in the hemodialysis liquid in the context of peritoneal dialysis, by adding to the bags used to carry out peritoneal dialysis.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9201331A FR2687070A1 (en) | 1992-02-06 | 1992-02-06 | Concentrated solution for haemodialysis with anticoagulant power for extra corporeal circulation. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9201331A FR2687070A1 (en) | 1992-02-06 | 1992-02-06 | Concentrated solution for haemodialysis with anticoagulant power for extra corporeal circulation. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2687070A1 true FR2687070A1 (en) | 1993-08-13 |
Family
ID=9426393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9201331A Pending FR2687070A1 (en) | 1992-02-06 | 1992-02-06 | Concentrated solution for haemodialysis with anticoagulant power for extra corporeal circulation. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2687070A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3004990A1 (en) * | 1980-02-11 | 1981-10-15 | Horst Prof. Dr.-Ing. 7250 Leonberg Chmiel | Blood sterilisation esp. in dialysis - using semipermeable membrane with absorber containing aggregation inhibitor and catalyst on face remote from blood |
| DE3406563A1 (en) * | 1984-02-23 | 1985-09-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Apparatus and method for removing heparin from blood or from a blood fraction and blood treatment system |
| WO1989003229A1 (en) * | 1987-10-07 | 1989-04-20 | Baxter International Inc. | Method for wetting plasmapheresis filter with anticoagulant |
-
1992
- 1992-02-06 FR FR9201331A patent/FR2687070A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3004990A1 (en) * | 1980-02-11 | 1981-10-15 | Horst Prof. Dr.-Ing. 7250 Leonberg Chmiel | Blood sterilisation esp. in dialysis - using semipermeable membrane with absorber containing aggregation inhibitor and catalyst on face remote from blood |
| DE3406563A1 (en) * | 1984-02-23 | 1985-09-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Apparatus and method for removing heparin from blood or from a blood fraction and blood treatment system |
| WO1989003229A1 (en) * | 1987-10-07 | 1989-04-20 | Baxter International Inc. | Method for wetting plasmapheresis filter with anticoagulant |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brophy et al. | AN-69 membrane reactions are pH-dependent and preventable | |
| KAPLAN et al. | Continuous arteriovenous hemofiltration: A report of six months' experience | |
| Kumar et al. | Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit | |
| US20090192137A1 (en) | Dialysis method | |
| Bellomo et al. | Blood purification in the intensive care unit: evolving concepts | |
| JP2014210780A (en) | Biocompatible dialysis fluids containing icodextrins | |
| JP2009131669A (en) | Bicarbonate-based solution in single container | |
| JP2009051850A (en) | Composition for treatment of renal failure comprising l-carnosine | |
| Bellomo et al. | Use of continuous haemodiafiltration: an approach to the management of acute renal failure in the critically ill | |
| Fine et al. | Extended hemodialysis in children with chronic renal failure | |
| Ronco et al. | Arteriovenous hemodiafiltration associated with continuous arteriovenous hemofiltration: a combined therapy for acute renal failure in the hypercatabolic patient | |
| FR2687070A1 (en) | Concentrated solution for haemodialysis with anticoagulant power for extra corporeal circulation. | |
| JP7034933B2 (en) | Dialysis concentrate | |
| Hothi et al. | Pediatric hemodialysis prescription, complications, and future directions | |
| JPH07136255A (en) | Composition for blood dialysis circuit and chamber for blood dialyzing circuit | |
| Sivalingam et al. | Haemodialysis | |
| SU722544A1 (en) | Hemodialysis method | |
| RU2218158C2 (en) | Method for preparing and carrying out plasmapheresis in podagra-suffering patients | |
| Böhler | Treatment of acute renal failure in intensive care patients | |
| Deep et al. | Continuous renal replacement therapy | |
| El-Reshaid et al. | Decreased aortic valve prosthesis-associated haemolysis after changing from haemodialysis to peritoneal dialysis | |
| Thornhill et al. | Current Status Of Hemodialysis In Veterinary Medicine And The Development Of The Canine Animal Model For Hemodialysis-Related Disorders In Man | |
| Ligeyo | The Principles And Practice Of Haehodialysis: The Experience At The Kenyatta National Hospital | |
| Sieberth | History and development of continuous renal replacement therapy (CRRT) | |
| Harshman et al. | Management of Pediatric Acute Kidney Injury |